Free Trial
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free PULM Stock Alerts

Pulmatrix (PULM) Competitors

Pulmatrix logo
$1.48 -0.09 (-5.73%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PULM vs. UPC, COCP, LPCN, CLRB, and TVRD

Should you buy Pulmatrix stock or one of its competitors? Pulmatrix's main competitors and comparable companies include Universe Pharmaceuticals (UPC), Cocrystal Pharma (COCP), Lipocine (LPCN), Cellectar Biosciences (CLRB), and Tvardi Therapeutics (TVRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pulmatrix compare to Universe Pharmaceuticals?

Pulmatrix (NASDAQ:PULM) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Universe Pharmaceuticals' return on equity of 0.00% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
PulmatrixN/A -125.65% -95.19%
Universe Pharmaceuticals N/A N/A N/A

Universe Pharmaceuticals has higher revenue and earnings than Pulmatrix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmatrix$7.81M0.73-$5.16M-$1.10N/A
Universe Pharmaceuticals$17.86M1.26-$3.67MN/AN/A

Pulmatrix has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Pulmatrix. Universe Pharmaceuticals' average media sentiment score of 0.98 beat Pulmatrix's score of 0.49 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Pulmatrix Neutral
Universe Pharmaceuticals Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Universe Pharmaceuticals beats Pulmatrix on 8 of the 10 factors compared between the two stocks.

How does Pulmatrix compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Cocrystal Pharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pulmatrix's return on equity of -125.65% beat Cocrystal Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cocrystal PharmaN/A -207.47% -123.33%
Pulmatrix N/A -125.65%-95.19%

Pulmatrix has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cocrystal PharmaN/AN/A-$8.83M-$0.76N/A
Pulmatrix$7.81M0.73-$5.16M-$1.10N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cocrystal Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Cocrystal Pharma had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.49 beat Cocrystal Pharma's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.

Company Overall Sentiment
Cocrystal Pharma Neutral
Pulmatrix Neutral

Summary

Pulmatrix beats Cocrystal Pharma on 8 of the 11 factors compared between the two stocks.

How does Pulmatrix compare to Lipocine?

Pulmatrix (NASDAQ:PULM) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Pulmatrix has higher revenue and earnings than Lipocine. Pulmatrix is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmatrix$7.81M0.73-$5.16M-$1.10N/A
Lipocine$1.98M8.53-$9.63M-$1.79N/A

Pulmatrix has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Lipocine had 9 more articles in the media than Pulmatrix. MarketBeat recorded 9 mentions for Lipocine and 0 mentions for Pulmatrix. Lipocine's average media sentiment score of 0.75 beat Pulmatrix's score of 0.49 indicating that Lipocine is being referred to more favorably in the news media.

Company Overall Sentiment
Pulmatrix Neutral
Lipocine Positive

Lipocine has a consensus price target of $4.00, indicating a potential upside of 95.12%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lipocine
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Pulmatrix has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Pulmatrix's return on equity.

Company Net Margins Return on Equity Return on Assets
PulmatrixN/A -125.65% -95.19%
Lipocine -755.39%-64.75%-57.62%

Summary

Lipocine beats Pulmatrix on 10 of the 16 factors compared between the two stocks.

How does Pulmatrix compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Pulmatrix. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Pulmatrix. Cellectar Biosciences' average media sentiment score of 0.68 beat Pulmatrix's score of 0.49 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Cellectar Biosciences Positive
Pulmatrix Neutral

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 517.98%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Pulmatrix has higher revenue and earnings than Cellectar Biosciences. Pulmatrix is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$21.79M-$3.84N/A
Pulmatrix$7.81M0.73-$5.16M-$1.10N/A

Pulmatrix's return on equity of -125.65% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -185.35% -115.42%
Pulmatrix N/A -125.65%-95.19%

Cellectar Biosciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences beats Pulmatrix on 9 of the 15 factors compared between the two stocks.

How does Pulmatrix compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pulmatrix's return on equity of -125.65% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tvardi TherapeuticsN/A -145.40% -91.11%
Pulmatrix N/A -125.65%-95.19%

Pulmatrix has higher revenue and earnings than Tvardi Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tvardi Therapeutics$7.14M2.15-$18.21M-$2.79N/A
Pulmatrix$7.81M0.73-$5.16M-$1.10N/A

Tvardi Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Tvardi Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 1,465.22%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tvardi Therapeutics is more favorable than Pulmatrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tvardi Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Pulmatrix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Pulmatrix. MarketBeat recorded 2 mentions for Tvardi Therapeutics and 0 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.49 beat Tvardi Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.

Company Overall Sentiment
Tvardi Therapeutics Neutral
Pulmatrix Neutral

Summary

Tvardi Therapeutics beats Pulmatrix on 10 of the 16 factors compared between the two stocks.

Get Pulmatrix News Delivered to You Automatically

Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PULM vs. The Competition

Export
MetricPulmatrixPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.40M$12.12B$7.17B$13.38B
Dividend YieldN/A2.65%2.53%17.32%
P/E Ratio-1.35799.73274.6226.19
Price / Sales0.69755.36608.2890.56
Price / CashN/A15.0827.2234.70
Price / Book0.6010.6911.276.40
Net Income-$5.16M$2.83B$3.49B$381.07M
7 Day Performance-7.44%-2.12%-1.59%-0.56%
1 Month Performance6.47%-6.52%-5.90%-4.42%
1 Year Performance-69.61%-4.33%8.19%1.89%

Pulmatrix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PULM
Pulmatrix
0.2057 of 5 stars		$1.48
-5.7%		N/A-67.8%$5.40M$7.81MN/A2
UPC
Universe Pharmaceuticals
0.7013 of 5 stars		$4.30
-4.9%		N/A-4.5%$22.71M$17.86MN/A216
COCP
Cocrystal Pharma
0.6009 of 5 stars		$1.15
+2.7%		N/A-5.4%$21.58MN/AN/A10
LPCN
Lipocine
4.1687 of 5 stars		$2.20
+1.9%		$4.00
+81.8%		-38.8%$17.81M$1.98MN/A14
CLRB
Cellectar Biosciences
3.0001 of 5 stars		$1.84
+1.1%		$11.00
+497.8%		-69.2%$17.20MN/AN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PULM) was last updated on 10/5/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel